United Therapeutics Corp

NASDAQ:UTHR 10:39:50 AM EDT

227.61

+2.50 (+1.11%)

Products

United Therapeutics Receives FDA Orphan Drug Designation For Treprostinil For The Treatment Of Idiopathic Pulmonary Fibrosis

Published: 12/09/2020 11:09 GMT

United Therapeutics Corp (UTHR) - United Therapeutics Receives FDA Orphan Drug Designation for Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis.
United Therapeutics Corp - Phase 3 Teton Study Planned in 2021 for Tyvaso in Patients With Idiopathic Pulmonary Fibrosis.